chemical

ABT 199

6960

10 mg (also 50 mg)

75 USD

6960

6960/10

ABT 199

Selective, high affinity Bcl-2 inhibitor; orally bioavailable

Bcl-2 Family Inhibitors

Small Molecules

10 mg (also 50 mg)

98%

868.45

?utm_source=distributor&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

Selective, high affinity Bcl-2 inhibitor (Ki 0.010 nM). Exhibits 4800-fold selectivity for Bcl-2 over Bcl-xL and Bcl-w, and displays no measurable activity at Mcl-1 (Ki 444 nM). Potently induces apoptosis in FL5.12-BCL-2 cells (EC50 = 261 nM) and reduces tumor burden in chronic lymphocytic leukemia (CLL) primary samples (EC50 = 3 nM). Shows reduced toxicity to platelets compared to similar compounds. Enhances efficacy of clinically relevant chemotherapy and immunotherapy drugs. Orally bioavailable. Exhibits binding to SARS-CoV-2 3C-like protease (3CLpro) active site in a virtual screen.

6960

ABT199 GDC 0199 GDC0199 Bcl-2 inhibitors inhibits induces apoptosis orally bioavailable selective high affinity SARS-CoV-2 3C-like protease severe acute respiratory syndrome coronavirus COVID-19 Venetoclax GDC-0199 Bcl-2 Family 3C and 3CL Proteases 6960,

Selective, high affinity Bcl-2 inhibitor; orally bioavailable

4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

C 45 H 50 ClN 7 O 7 S

C45H50ClN7O7S

1257044-40-8

75

75 USD

Venetoclax, GDC-0199

Store at -20°C